Novartis AG ADR (NVS)vsOlink Holding AB ADR (OLK)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
OLK
Olink Holding AB ADR
$26.08
0.00%
HEALTHCARE · Cap: $3.24B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 33008% more annual revenue ($56.58B vs $170.89M). NVS leads profitability with a 23.9% profit margin vs -19.7%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
OLK
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for OLK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
4.7% revenue growth
0.0% earnings growth
ROE of -7.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : OLK
OLK has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : OLK
The primary concerns for OLK are Revenue Growth, EPS Growth, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while OLK is a turnaround play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
OLK is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 19/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Olink Holding AB ADR
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Olink Holding AB (publ) provides various products and services for academic, government, biopharmaceutical, biotechnology and other institutions focused on life science research. The company is headquartered in Uppsala, Sweden.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?